Adicet Bio director granted 4,200 stock options

Adicet Bio, Inc. director Andrew Sinclair received a grant of stock options as part of his board compensation.

Rhea-AI Filing Summary

Adicet Bio, Inc. director Andrew Sinclair received a grant of stock options as part of his board compensation. He was awarded 4,200 stock options to purchase Adicet Bio common stock at an exercise price of $8.10 per share. These options expire on June 20, 2036. They vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders after the grant date, subject to his continued service on the board. Following this award, Sinclair holds 4,200 derivative securities linked to Adicet Bio common stock.

Insider Trade Summary

Grant/Award: 4,200 shares

Grant/Award 1 txn

Insider Sinclair Andrew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	4,200	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 4,200 contracts (Direct)

Footnotes (1)

1. F1. These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

Key Figures

Options granted: 4,200 options Exercise price: $8.10 per share Expiration date: June 20, 2036 +3 more

6 metrics

Options granted 4,200 options Director stock option grant

Exercise price $8.10 per share Stock option exercise price

Expiration date June 20, 2036 Option term end

Shares underlying options 4,200 shares Underlying common stock

Vesting condition Earlier of 1-year anniversary or next annual meeting Subject to continued board service

Total derivative holdings after grant 4,200 options Post-transaction position

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 8.1000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-20T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Adicet Bio (ACET) report for Andrew Sinclair?

Adicet Bio reported that director Andrew Sinclair received a grant of 4,200 stock options to buy common shares at an exercise price of $8.10. This is a compensation-related award, not an open-market purchase or sale of existing shares.

How many Adicet Bio (ACET) stock options were granted to Andrew Sinclair?

Andrew Sinclair was granted 4,200 stock options linked to Adicet Bio common stock. These options give him the right to buy up to 4,200 shares at a fixed $8.10 exercise price if and when the options vest and are exercised.

What is the exercise price and expiration date of Andrew Sinclair’s Adicet Bio options?

The granted options have an exercise price of $8.10 per share and an expiration date of June 20, 2036. This means Sinclair can choose to exercise the options at $8.10 any time after vesting and before they expire in 2036.

When do Andrew Sinclair’s Adicet Bio (ACET) stock options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders after the grant. Vesting is conditioned on Sinclair’s continued service on Adicet Bio’s board of directors through that vesting date.

Did Andrew Sinclair buy or sell Adicet Bio shares in the open market?

No open-market buy or sell of Adicet Bio shares was reported. The Form 4 shows a grant of 4,200 stock options as compensation, not a purchase or sale of existing common stock in the market by Sinclair.

How many Adicet Bio derivative securities does Andrew Sinclair hold after this grant?

After this transaction, Andrew Sinclair holds 4,200 derivative securities in the form of stock options. These options represent the right to acquire up to 4,200 Adicet Bio common shares at the fixed $8.10 exercise price, subject to vesting and future exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sinclair Andrew

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.1	06/21/2026		A		4,200		(1)	06/20/2036	Common Stock	4,200	$0	4,200	D

Explanation of Responses:

1. These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

	/s/ Nick Harvey, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)